Clifford Chance advises CVC on US$105 million investment in Venturepharma Group in China
Leading international law firm Clifford Chance has acted for funds advised by CVC Asia Pacific Limited on its US$105 million investment in convertible bonds issued by Venturepharma Group in China.
Beijing partner Terence Foo who led the core team said, "We were delighted to partner with CVC on yet another successful investment in China. This deal highlights the strong interest by private equity in China's healthcare and pharmaceutical sector, which is set to become one of the largest markets in the world in the coming few years."
Terence was assisted by counsel Wei He and associate Menghan Wang. They received support from Tokyo partner Andrew Whan and Hong Kong associates Janet Jiang and Maureen Ho as well as trainee Wendy Kam on Hong Kong matters, Shanghai partner Glen Ma on healthcare sector issues, Hong Kong partner Wendy Wysong and London associate Chris Yates and Washington associate Megan Gordon on compliance issues, and Beijing partner Maggie Lo and associate Chun Kit Mak on security issues.
Venturepharma is an integrated specialty pharmaceutical company that has a broad product portfolio in a number of fast growing therapeutic areas, particularly Central Nerve System (CNS) and Anti-Allergy. The Company has strong capabilities in product development, manufacturing and sales. Venturepharma holds a large number of product rights and patents in China, one of the highest in the industry. CVC's investment will be used to fund the growth expansion of the Company and further strengthen its R&D, manufacturing and sales functions.